Yago Garitaonaindía, Translational Research Fellow at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, shared on X:
“Waking up with another milestone in SCLC coming from WCLC26.
TAISHAN-302: B7-H3 ADC Tam-Peli vs topotecan after platinum ± IO (n=451, China).
mOS 13.3 vs 9.4 mo (HR 0.46) mPFS 7.4 vs 2.8 (HR 0.29) ORR 59% vs 10% G≥3 AEs 55% vs 78%
- OS ~tarlatamab, different mechanism
- China-only, open-label, short FU.”
Title: Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Authors: Yuanyuan Zhao, Hongxu Liu, Xiangjiao Meng, Zhihua Liu, Yan Yu, YulongZheng, Longhua Sun, Runxiang Yang, Jian Liu, Yanqiu Zhao, Lin Wu, Lei Yang, Zhiye Zhang, Mingjun Li, Peng Zhang, Yan Zhang, Hua Zhong, Jiuwei Cui, Zhangzhou Huang, Yanwei Yin, Manxiang Li, Fan Tong, Dan Xue, Dongqing Lv, Xufeng Li, Xian Zhang, Steve Chin, Jiaqiang Cai, Tongtong Xue, Yan Huang, Hongyun Zhao, Li Zhang.
Read the full article.
You can also read:
